

## UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	ı	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/915,060		07/25/2001	Sigrid Cornelis	4976US 6077	
24247	7590	11/23/2001			
TRASK BRITT				EXAMINER	
P.O. BOX 2	550	· · · · · · · · · · · · · · · · · · ·	PAPPU, SITA S		
SALT LAK	E CITY,	JT 84110			
				ART UNIT	PAPER NUMBER
				1632	
			DATE MAILED: 11/23/2001		

Please find below and/or attached an Office communication concerning this application or proceeding.

· 3		Application No.	Applicant(s)				
	_	09/915,060	CORNELIS ET AL.				
	Office Action Summary	Examiner	Art Unit				
		Sita S Pappu	1632				
	The MAILING DATE of this communication app						
Period for Reply							
TH - E a - If - If - A	EHORTENED STATUTORY PERIOD FOR REPLY E MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.13 fter SIX (6) MONTHS from the mailing date of this communication. The period for reply specified above is less than thirty (30) days, a reply NO period for reply is specified above, the maximum statutory period wailure to reply within the set or extended period for reply will, by statute, ny reply received by the Office later than three months after the mailing armed patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply  within the statutory minimum of thirty (3  will apply and will expire SIX (6) MONTH's  cause the application to become ABAN	o) days will be considered timely.  S from the mailing date of this communication.				
1)[	Responsive to communication(s) filed on						
2a)[		is action is non-final.					
3)[	Since this application is in condition for allowa closed in accordance with the practice under						
Disposition of Claims							
4)[	☑ Claim(s) <u>1-22</u> is/are pending in the application						
	4a) Of the above claim(s) is/are withdraw	vn from consideration.					
5)[	Claim(s) is/are allowed.						
6)[	Claim(s) is/are rejected.						
7)[	Claim(s) is/are objected to.						
8)[	Claim(s) <u>1-22</u> are subject to restriction and/or e	election requirement.					
Applic	ation Papers						
9)[	$\centcal{T}$ The specification is objected to by the Examine	r.					
10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
	The oath or declaration is objected to by the Exa	aminer.					
	y under 35 U.S.C. §§ 119 and 120						
•	Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 1	19(a)-(d) or (f).				
	a) ☐ All b) ☐ Some * c) ☐ None of:						
	1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents	•	-				
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) ☐ The translation of the foreign language provisional application has been received.  15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
2) 🔲 N	otice of References Cited (PTO-892) otice of Draftsperson's Patent Drawing Review (PTO-948) formation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Info	nmary (PTO-413) Paper No(s) rmal Patent Application (PTO-152)				

Application/Control Number: 09/915,060

Art Unit: 1632

## **DETAILED ACTION**

Claims 1-22 are pending in the instant application.

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-15, 16-19, 22, drawn to an isolated and/or recombinant nucleotide sequence enabling a cell cycle dependent initiation of translation of mRNA, a chimeric gene, a vector, a eukaryotic host cell, and a method for cap-independent translation of mRNA in a cell, classified in class 536, subclass 23.1.
- Claims 20, 21, drawn to a pharmaceutical composition for treating and/or preventing a disease in a subject by gene therapy and a method of treating a disease in a subject, classified in class 514, subclass 44.

The inventions are distinct, each from the other because of the following reasons:

Invention I is directed to an isolated nucleic acid molecule and the method of using it in cap-independent translation of mRNA, while Invention II is directed to gene therapy using a pharmaceutical composition for treating and/or preventing a disease in a subject.

Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the product of Invention I

Application/Control Number: 09/915,060

Art Unit: 1632

can be used in the method of Invention I, which is cap-independent translation of mRNA in a cell. The method of Invention I is materially different from the method of Invention II. The two methods require materially different protocols and are distinct.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, and because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sita S Pappu whose telephone number is (703) 305-5039. The examiner can normally be reached on Mon-Fri (9:00 AM - 5:00 PM).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Karen Hauda can be reached on (703) 305-6608. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 308-8724 for After Final communications.

Application/Control Number: 09/915,060

Art Unit: 1632

Page 4

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group Patent Analyst whose telephone number is (703) 305-2758.

S. Pappu November 16, 2001 anne-Marie Baker PATENT EXAMINER